One in 3 high blood pressure patients failing to take medication

One in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals, a new study led by the University of Leicester has suggested. A study on 1,400 hypertensive patients, conducted in collaboration between the Universities of Leicester (lead authors Dr Pankaj Gupta, Dr Prashanth Patel from the Department of Cardiovascular Sciences at the University of Leicester), Manchester (Prof M Tomazweski) and Czech Republic (Prof J Widimsky) has used a novel urine test to find that non-adherence to prescribed medications is around 30-40%.

Non-adherence to medications has been known since the time of Hippocrates and has been found to be one of the important reasons for the lack of blood pressure control in at least 50% of the patients in the study - despite the availability of good medicines.

Non-adherence leads to poorer cardiovascular outcomes and is thought to cost $100 billion to the US health economy.

A crucial reason for the lack of progress in improving adherence has been the previous lack of a clinically useful objective measure to show when people are not taking their prescribed medicine.

The research team has worked to develop a robust and reliable biochemical screening method to assess for non-adherence to antihypertensive medications in urine or blood using a technique called liquid chromatography-tandem mass spectrometry.

The team has set up a National Centre for Adherence Testing (NCAT, This email address is being protected from spambots. You need JavaScript enabled to view it.) at Leicester's Hospitals and receive samples from around 25 hypertension clinics across UK.

The study showed that more than 41.6% of the UK cohort and 31.5% of the Czech cohort were non-adherent to their anti-hypertensive medications.

Moreover 14.5% of the UK and 12% of the Czech cohort were not taking any medications. Crucially non-adherence was related to the number of prescribed medications with the risk increasing by >75% with each increase in medication and it was highest with diuretics.

As well as the above, younger patients and females were found to have an increased risk of non-adherence to prescribed medications.

Dr Gupta said: "Given the high prevalence of non-adherence, we should assess patients, particularly those on multiple antihypertensive medications or those who do not have an expected response to treatment"

Dr Patel said: "This is a simple, relatively inexpensive and a robust test. It and has anecdotally changed the management of hypertension in many centres who use the test."

The researchers hope to ascertain whether non-adherent patients, on follow up, improved their medication taking behaviour and if adherence testing led to an improvement in blood pressure.

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M.
Risk Factors for Nonadherence to Antihypertensive Treatment.
Hypertension. 2017 Jun;69(6):1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis' Ultibro® Breezhaler® significantly impro…

Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) pati...

New Novartis Entresto® real world evidence data sh…

Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejec...

FDA approves pill with sensor that digitally track…

The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) ...

Scientists find natural mimetics of anti-cancer …

Researchers from the Biogerontology Research Foundation, Insilico Medicine, Life Extension and other institutions announce the publication of a landmark study in the jour...

Novartis, ASCP and ACS join forces to fight cancer…

Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to ca...

World's smallest tape recorder is built from micro…

Through a few clever molecular hacks, researchers at Columbia University Medical Center have converted a natural bacterial immune system into a microscopic data recorder...

Using social media big data to combat prescription…

Researchers at Dartmouth, Stanford University, and IBM Research, conducted a critical review of existing literature to determine whether social media big data can be used...

Discovery of a promising medication for amyotrophi…

Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medi...

Sclerosis medicine can fight multi-resistant bacte…

Encountering bacteria with innocent names such as Pseudomonas aeruginosa and Enterobacteriaceae can lead to hospitalisation and - in a worst-case scenario - can also be l...

Mushrooms are full of antioxidants that may have a…

Mushrooms may contain unusually high amounts of two antioxidants that some scientists suggest could help fight aging and bolster health, according to a team of Penn State...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]